At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01801 INNOVENT BIO
Closed 08-27 16:08:31
107.600
-2.200
-2.00%
High111.600
Low106.100
Vol14.12M
Open110.800
D1 Closing109.800
Amplitude5.01%
Mkt Cap187.65B
Tradable Cap187.65B
Total Shares1.74B
T/O1.52B
T/O Rate0.81%
Tradable Shares1.74B
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Nomura Adjusts Innovent Biologics' Price Target to HK$125 From HK$105, Keeps at Buy
Mainland Benchmarks Edge Higher in Morning Trade; Nonferrous Metals and Brokerages Lead While Optical Modules Retreat; Hang Seng and Tech Index Climb Over 1% on Biotech Surge
Innovent Biologics Inc is an investment holding company principally engaged in the research, development, production and sales of innovative medicines for the treatment of diseases such as cancer, cardiovascular and metabolic (CVM), autoimmune and eye diseases. The pipeline covering monoclonal antibodies, multi-specific antibodies, immuno-cytokine, antibody-drug conjugates (ADCs), cell therapy and small molecules. The Company’s main products include TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), Pemazyre (pemigatinib) and others. The Company mainly conducts its businesses within domestic and overseas markets.